Biography

David Hsieh, M.D., is an Assistant Professor in the Department of Internal Medicine at UT Southwestern Medical Center and a member of its Division of Division of Hematology and Oncology. He specializes in the treatment of hepatocellular carcinoma and bile duct cancers. 

Originally from Tucson, Ariz., Dr. Hsieh earned his medical degree at the University of Arizona College of Medicine. He completed a residency in internal medicine at Mount Auburn Hospital in Cambridge, Massachusetts, and completed advanced training  through a fellowship in hematology and oncology at UT Southwestern. 

Board-certified in internal medicine and medical oncology, Dr. Hsieh joined the UT Southwestern faculty in 2019.

Dr. Hsieh’s research interests include translational studies to understand mechanisms behind the variable effectiveness of cancer therapies between patients and developing new therapies for gastrointestinal cancers through clinical trials. He also conducts research on processes, policies, and biases in scientific research and medicine.

His awards and honors include an Early Career Investigator Award from the Cancer Prevention and Research Institute of Texas.

 

 

Research Interest
  • Immunotherapy
  • Liver Cancer
  • Mechanisms of Drug Resistance
  • Predictive biomarkers

Publications

Featured Publications LegendFeatured Publications

Genetic features and therapeutic relevance of emergent circulating tumor DNA alterations in refractory non-colorectal gastrointestinal cancers.
Hsiehchen D, Bucheit L, Yang D, Beg MS, Lim M, Lee SS, Kasi PM, Kaseb AO, Zhu H, Nat Commun 2022 Dec 13 1 7477
Clonal hematopoiesis and differential outcomes after immune checkpoint blockade.
Hsiehchen D, Sfreddo HJ, Zhao K, Han CY, Morris LGT, Cancer Cell 2022 Oct 40 10 1071-1072
Adherence to a Federal Hospital Price Transparency Rule and Associated Financial and Marketplace Factors.
Haque W, Ahmadzada M, Janumpally S, Haque E, Allahrakha H, Desai S, Hsiehchen D, JAMA 2022 06 327 21 2143-2145
Impact of tumor mutational burden on checkpoint inhibitor drug eligibility and outcomes across racial groups.
Hsiehchen D, Espinoza M, Valero C, Ahn C, Morris LGT, J Immunother Cancer 2021 11 9 11
DNA Repair Gene Mutations as Predictors of Immune Checkpoint Inhibitor Response beyond Tumor Mutation Burden.
Hsiehchen D, Hsieh A, Samstein RM, Lu T, Beg MS, Gerber DE, Wang T, Morris LGT, Zhu H, Cell Rep Med 2020 Jun 1 3
Nearing saturation of cancer driver gene discovery.
Hsiehchen D, Hsieh A, J Hum Genet 2018 Sep 63 9 941-943
Multinational teams and diseconomies of scale in collaborative research.
Hsiehchen D, Espinoza M, Hsieh A, Sci Adv 2015 Sep 1 8 e1500211